Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweight/obesity involve age-associated fat mass loss – results of an exploratory study

PURPOSE: Roflumilast (Daliresp, Daxas) is a FDA-approved phosphodiesterase 4 (PDE4) inhibitor for the treatment of moderate-to-severe chronic obstructive pulmonary disease. In mice and in limited human studies, this oral medication can cause weight loss and improve insulin sensitivity. We set out to...

Descripción completa

Detalles Bibliográficos
Autores principales: Muo, Ijeoma M, MacDonald, Sandra D, Madan, Ritu, Park, Sung-Jun, Gharib, Ahmed M, Martinez, Pedro E., Walter, Mary F, Yang, Shanna B, Rodante, Justin A, Courville, Amber B, Walter, Peter J, Cai, Hongyi, Glicksman, Michael, Guerrieri, Gioia M, Ben-Dor, Rivka R, Ouwerkerk, Ronald, Mao, Stephanie, Chung, Jay H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542328/
https://www.ncbi.nlm.nih.gov/pubmed/31213865
http://dx.doi.org/10.2147/DMSO.S182953

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542328/
https://www.ncbi.nlm.nih.gov/pubmed/31213865
http://dx.doi.org/10.2147/DMSO.S182953

Ejemplares similares